8-K: INmune Bio Achieves 24-Month Stability for XPro and Files Patent for Novel Immunogenicity Assay

INmune Bio announces successful completion of 24-month stability validation for XPro and files a patent application for a novel anti-drug antibody assay.

Summary

• INmune Bio has successfully completed extended stability validation for XPro, confirming its stability for 24 months when stored in solution at 2-8C.
• This 24-month stability is consistent with other pegylated cytokines and allows the company to use established global supply chain systems.
• The company has also developed a novel anti-drug antibody assay for XPro that mitigates false positive readings associated with conventional methods.
• A patent application has been filed for this new assay, which uses a novel ACE-AG format.
• Details of the assay will be presented at the 18th Workshops on Recent Issues in Bioanalysis (WRIB) on May 7, 2024.
• INmune Bio remains on track with its Phase 2 clinical trial for XPro in the treatment of Alzheimer's Disease.

Sentiment

Score: 8

Explanation: The document presents positive news regarding the stability of XPro and the development of a novel assay, which are crucial for the drug's progress. The company is on track with its clinical trials, and the management commentary is optimistic. However, the risks associated with clinical trials and funding are acknowledged.

Positives

• The 24-month stability of XPro allows for the use of established global distribution systems, reducing logistical challenges.
• The novel anti-drug antibody assay addresses a unique challenge related to XPro's mechanism, enhancing the reliability of testing.
• The patent application for the new assay adds value to the XPro franchise.
• The company is on track with its Phase 2 clinical trial for XPro in Alzheimer's Disease.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding is necessary for continued operations, research, and development.
• Regulatory approval for XPro is not guaranteed.

Future Outlook

The company plans to continue its Phase 2 clinical trial for XPro in Alzheimer's Disease and move towards Phase III and commercial applications. They also aim to provide XPro in a pre-filled syringe format for easy home storage and self-administration.

Management Comments

• RJ Tesi, MD, stated that the 24-month stability is essential for their plans to use XPro as they move towards Phase III and commercial applications.
• Joshua Schoonover, the Company's General Counsel, noted that the new assay is the product of a unique challenge and applied innovation, adding value to the XPro1595 franchise.

Industry Context

The announcement is positive for INmune Bio as it demonstrates progress in the development of XPro, a key product candidate. The 24-month stability is important for commercialization and aligns with industry standards for similar biologics. The development of a novel immunogenicity assay addresses a specific challenge related to XPro's unique mechanism, which could be a competitive advantage.

Comparison to Industry Standards

• The 24-month stability claim for XPro is consistent with other pegylated cytokines, such as alpha-interferon, which is a common benchmark in the pharmaceutical industry.
• The use of temperature-controlled and monitored shipment of liquid-formulation drugs at 2-8C is a routine practice in the pharmaceutical industry, and XPro's stability allows it to utilize these established systems.
• The development of a novel anti-drug antibody assay is a significant step, as conventional methods can be problematic for drugs with unique mechanisms like XPro. This is similar to other companies that have had to develop specific assays for their novel biologics.

Stakeholder Impact

• Shareholders will likely view the news positively as it demonstrates progress in the development of XPro.
• Patients with Alzheimer's Disease may benefit from the development of XPro as a potential treatment.
• The company's employees may be positively impacted by the progress of the company's key product.

Next Steps

• The company will present details of the new anti-drug antibody assay at the WRIB conference on May 7, 2024.
• The company will continue its Phase 2 clinical trial for XPro in Alzheimer's Disease.
• The company will move towards Phase III and commercial applications for XPro.

Key Dates

Keywords

XPro, Stability Validation, Anti-Drug Antibody Assay, Immunogenicity, Alzheimer's Disease, Clinical Trial, Patent Application, Supply Chain, INmune Bio, Biotechnology